本模块目录 · 33 节
- 导语:这本手册能帮你解决什么
- 第一部分 医学论文英文高频句式与核心词汇
- 1.1 先建立整体认知:IMRaD 结构与“积木式”写作
- 1.2 题名(Title):结构、句式与规范
- 1.3 摘要(Abstract):四要素标准句式
- 1.4 引言(Introduction):漏斗结构与高频句式
- 1.5 方法(Methods):时态语态与各模块句式
- 1.6 结果(Results):数据、图表与显著性描述
- 1.7 讨论(Discussion):对比、解释、局限与结论
- 1.8 声明类表达:致谢、利益冲突、基金、数据可用性
- 1.9 医学专业核心词汇与高频连接词
- 第二部分 零基础英文写作工具指南
- 2.1 工具使用总原则与数据保密
- 2.2 翻译工具:正确用法与避坑
- 2.3 语法纠错工具:正确用法与避坑
- 2.4 生成式 AI:提示词模板与学术诚信红线
- 2.5 改写降重工具的风险
- 2.6 推荐工具组合工作流
- 第三部分 国际投稿沟通礼仪
- 3.1 总体原则:正式、简洁、礼貌、留痕
- 3.2 投稿信(Cover Letter):结构与完整模板
- 3.3 与编辑往来邮件:常用场景模板
- 3.4 审稿回复(Response to Reviewers):点对点规范
- 3.5 四类审稿决定的应对
- 3.6 称呼、落款、附件与语气细节
- 第四部分 “一带一路”区域医学期刊投稿特点
- 4.1 选刊先看什么:索引、费用与诚信核查
- 4.2 中亚地区:多语种并存与 Scopus 转型
- 4.3 东南亚地区:与国际规范接轨、区域索引成熟
- 4.4 中东地区:英文出版、伦理与注册把关严格
- 4.5 非洲地区:本地疾病议题友好、声明要求明确
- 4.6 区域对照表与通用投稿检查清单
- 结语:投稿前最终检查清单与心态建议
导语:这本手册能帮你解决什么
一线临床工作者往往“重临床、轻科研”:日常诊疗经验丰富,却缺乏系统的科研训练,对论文结构、英文表达、出版规则和投稿流程认知不足。很多人手里有病例、有数据,却卡在两道坎上——一是英文写作关,不知道规范的学术句子怎么写;二是国际投稿关,不了解编辑邮件、审稿回复和期刊规则,担心“失礼”或踩坑。
这本手册正是为解决这两道坎而写,内容匹配“一带一路”国际医学期刊的英文投稿需求。全篇以中文讲解 + 可直接套用的英文模板呈现,英文部分均为国际医学期刊中真实、高频、地道的表达,方括号 [ ] 内为需要你替换的占位符。即使英文基础薄弱,也可以像“搭积木”一样,先套骨架句式,再填入自己的专业内容。
手册分为四部分:第一部分给出论文各章节的高频句式与核心词汇;第二部分讲零基础也能用好的写作工具及避坑点;第三部分规范编辑邮件与审稿回复的沟通礼仪;第四部分梳理中亚、东南亚、中东、非洲等区域期刊的投稿特点。建议先通读建立全局认知,正式写作时再回到对应章节直接取用模板。
第一部分 医学论文英文高频句式与核心词汇
1.1 先建立整体认知:IMRaD 结构与“积木式”写作
国际医学论文普遍采用 IMRaD 结构,即 Introduction(引言)、Methods(方法)、Results(结果)、Discussion(讨论),再加上题名(Title)、摘要(Abstract)和关键词(Keywords)。各部分承担不同任务,对应不同的“标准句式库”。所谓“积木式”写作,就是先按章节搭好句式骨架,再把自己的研究对象、数据和结论填进去,而不必从零造句。
动笔前先掌握三条语言规则:
- 时态:描述“本研究做了什么、得到了什么”(方法、结果)多用一般过去时;陈述公认事实、背景知识和结论性观点多用一般现在时;回顾“截至目前的研究进展”常用现在完成时。
- 语态:传统医学写作偏好被动语态以显客观(如 Patients were enrolled),但现代期刊同样接受以 we 开头的主动语态(如 We enrolled patients),关键是全文风格统一。
- 简洁:学术英语追求准确、简洁、客观,避免口语化、夸张修饰和冗余表达,否定、数字和单位尤其要反复核对。
1.2 题名(Title):结构、句式与规范
题名是论文的“第一检索入口”,要求准确、简明、可检索,尽量使用规范术语和研究设计名称,避免缩写和空泛的夸张词。常见有三种结构:
- 名词短语型:直接点明研究对象与设计,最常见;
- 主副标题型:用冒号分隔,前半讲主题、后半讲设计或范围;
- 设计描述型:在题名中直接写明 Randomized Controlled Trial、Meta-analysis、Case Report 等。
可直接套用的高频题名模板:
Efficacy and Safety of [Drug/Intervention] in Patients with [Disease]: A Randomized, Double-Blind, Placebo-Controlled Trial
[Intervention] versus [Comparator] for [Condition]: A Systematic Review and Meta-analysis
Prevalence of [Condition] among [Population]: A Cross-Sectional Study in [Region/Country]
Association between [Exposure] and [Outcome] in [Population]: A Retrospective Cohort Study
Effect of [Intervention] on [Primary Outcome] in Patients with [Disease]: A Multicenter, Open-Label Study
[Disease] Presenting as [Unusual Feature]: A Case Report and Review of the Literature
规范要点:一般不使用非公知缩写;不建议用 “Study on the Effect of ...” 这类空泛开头;病例报告通常以 “A Case Report” 结尾;题名长度按目标期刊要求控制,投稿前务必查看作者指南。
1.3 摘要(Abstract):四要素标准句式
多数医学期刊采用结构式摘要,依次包含背景/目的(Background/Objective)、方法(Methods)、结果(Results)和结论(Conclusion)。摘要应独立自明,且所有结果都必须有正文支持。下面按要素给出高频句式。
1.3.1 背景与目的(Background / Objective)
[Disease] remains a major public health challenge, affecting approximately [N] people worldwide.
However, evidence regarding [topic] in [population] remains limited and inconsistent.
This study aimed to evaluate the efficacy and safety of [intervention] in patients with [disease].
We sought to determine whether [exposure] is associated with [outcome].
The objective of this study was to investigate the prevalence and risk factors of [condition].
1.3.2 方法(Methods)
We conducted a prospective randomized controlled trial / retrospective cohort study / cross-sectional survey at [institution].
A total of [N] eligible patients were enrolled and randomly assigned in a 1:1 ratio to the intervention or control group.
The primary outcome was [endpoint]; secondary outcomes included [endpoint A] and [endpoint B].
Data on [variables] were collected from medical records and analyzed using [software/statistical method].
1.3.3 结果(Results)
Overall, [N] participants completed the study and were included in the final analysis.
The primary outcome was significantly improved in the intervention group compared with the control group (mean difference, [X]; 95% CI, [X to X]; P = [X]).
The incidence of [event] was [X]% in the intervention group versus [X]% in the control group (P < 0.05).
No significant difference was observed between the two groups in terms of [variable] (P = [X]).
Multivariate analysis showed that [factor] was an independent predictor of [outcome] (OR, [X]; 95% CI, [X to X]).
1.3.4 结论(Conclusion)
In this study, [intervention] significantly improved [outcome] compared with [comparator].
These findings suggest that [intervention] may be an effective and safe option for patients with [disease].
Our results support the use of [approach] in [clinical setting].
Further large-scale, multicenter studies are warranted to confirm these findings.
1.4 引言(Introduction):漏斗结构与高频句式
引言遵循“漏斗式”逻辑:从宏观背景切入,回顾已知证据,指出研究缺口(gap),最后落到本研究的目的与假设。篇幅通常 3–5 段,“研究缺口”是全篇最关键的逻辑枢纽。
1.4.1 背景与已知
[Disease] is one of the leading causes of morbidity and mortality worldwide.
Over the past decades, the incidence of [disease] has increased markedly, particularly in [region].
Accumulating evidence suggests that [factor] plays an important role in [process].
Previous studies have demonstrated that [intervention] can improve [outcome].
Several treatment options, including [A] and [B], are currently available.
1.4.2 指出研究缺口(关键)
However, little is known about [topic] in [specific population].
However, data on [outcome] in [region/setting] remain scarce.
To date, no study has examined the effect of [intervention] on [outcome].
It remains unclear whether [factor] is associated with [outcome].
Moreover, previous findings have been inconsistent, and the evidence is insufficient to guide clinical practice.
1.4.3 落到本研究
Therefore, the present study aimed to investigate [objective].
To address this gap, we evaluated [intervention] in patients with [disease].
We hypothesized that [intervention] would be superior to [comparator] in improving [outcome].
1.5 方法(Methods):时态语态与各模块句式
方法部分的核心要求是“可重复”:同行据此能够复现你的研究。统一使用一般过去时,按研究设计、对象、干预、指标、统计、伦理等子模块组织。
1.5.1 研究设计与对象
This was a single-center, retrospective, observational study conducted at [hospital] between [month/year] and [month/year].
Adult patients aged 18 years or older with a confirmed diagnosis of [disease] were eligible for inclusion.
Patients with [condition A], [condition B], or incomplete clinical data were excluded.
A consecutive sample of [N] patients was recruited for this study.
The sample size was calculated to detect a difference of [X] with a power of 80% and a two-sided alpha of 0.05.
1.5.2 干预、分组与测量
Patients were randomly assigned in a 1:1 ratio to receive either [intervention A] or [comparator B].
The intervention group received [treatment], whereas the control group received [placebo/standard care].
The primary endpoint was [outcome], and safety was assessed throughout the study period.
[Variable] was measured using [instrument/assay] at baseline and at [time points].
Blood samples were collected after an overnight fast and analyzed within [time].
1.5.3 统计分析
Continuous variables are expressed as mean ± standard deviation (SD) and were compared using the independent-samples t-test.
Non-normally distributed variables are presented as median and interquartile range (IQR) and were compared using the Mann–Whitney U test.
Categorical variables are presented as counts and percentages and were compared using the chi-square test or Fisher’s exact test.
Multivariate logistic regression was performed to identify independent predictors of [outcome].
A two-sided P value < 0.05 was considered statistically significant.
All statistical analyses were performed using SPSS version [X] / R version [X].
1.5.4 伦理与注册
This study was approved by the Institutional Review Board (Ethics Committee) of [institution] (approval No. [XXX]).
Written informed consent was obtained from all participants prior to enrollment.
The study was conducted in accordance with the principles of the Declaration of Helsinki.
This trial was registered with [registry] under registration number [XXX].
1.6 结果(Results):数据、图表与显著性描述
结果部分按“先基线、后结局”的顺序客观呈现,不做主观解释(解释放在讨论)。数据与图表相互配合,注意正文中正确引用表号、图号。
The baseline characteristics of the two groups are summarized in Table 1.
The groups were well matched, with no significant differences in age, sex, or comorbidities (all P > 0.05).
Compared with baseline, [variable] decreased significantly from [X] to [X] in the intervention group (P < 0.001).
The improvement was significantly greater in the intervention group than in the control group (P = [X]).
As shown in Figure 1, the rate of [event] declined gradually over the follow-up period.
The detailed results of the subgroup analysis are presented in Table 2.
No significant difference was found between the groups with respect to [variable] (P = [X]).
No serious adverse events were reported during the study period.
1.7 讨论(Discussion):对比、解释、局限与结论
讨论部分先回应主要发现,再与既往文献对比、解释机制与意义,坦诚说明局限,最后给出结论与展望。注意不要简单重复结果,而要回答“这意味着什么”。
1.7.1 回应发现与文献对比
In this study, we found that [main finding].
Our findings are consistent with those of previous studies reporting [result].
In contrast to earlier work, we observed that [result].
A possible explanation for this discrepancy is [reason].
The underlying mechanism may be attributed to [mechanism].
1.7.2 临床意义
These results have important clinical implications for the management of [disease].
Our findings provide evidence supporting [practice] in [setting].
This approach may offer a practical option, especially in resource-limited settings.
1.7.3 研究局限(必备)
Several limitations of this study should be acknowledged.
First, the single-center design and relatively small sample size may limit the generalizability of our findings.
Second, the retrospective, observational nature of the study precluded causal inference.
In addition, some variables relied on self-reporting, which may be subject to recall bias.
Finally, residual confounding cannot be completely excluded.
1.7.4 结论与展望
Despite these limitations, our study provides evidence that [conclusion].
Future large-scale, multicenter, prospective studies are needed to validate these findings.
Further research is also warranted to clarify the long-term effects of [intervention].
1.8 声明类表达:致谢、利益冲突、基金、数据可用性
国际期刊普遍要求随稿提交各类声明,句式固定、可直接套用,关键是真实填写。
Acknowledgments: We thank [colleagues/staff] for their contribution to data collection.
Conflicts of Interest: The authors declare that they have no competing interests.
Conflicts of Interest: The authors declare the following financial interests / personal relationships: [details].
Funding: This work was supported by [funder] under grant number [XXX].
Data Availability Statement: The data supporting the findings of this study are available from the corresponding author upon reasonable request.
Informed Consent: Written informed consent was obtained from all participants included in the study.
作者贡献(Author Contributions)通常采用 CRediT 分类表述:
Conceptualization, A.B. and C.D.; methodology, A.B.; formal analysis, E.F.; writing—original draft preparation, A.B.; writing—review and editing, C.D.; supervision, G.H. All authors have read and agreed to the published version of the manuscript.
1.9 医学专业核心词汇与高频连接词
下表汇总学术医学论文中最常用的动词、程度副词、逻辑连接词、易混词和拉丁缩写,建议结合自己的研究方向建立个人术语表,并对照 MeSH 等权威来源核对专业名词。
| 类别 | 高频表达(英文)及含义 |
|---|---|
| 高频动词 | investigate 调查;evaluate 评估;assess 评定;examine 检查;determine 确定;demonstrate 证实;indicate 表明;suggest 提示;reveal 揭示;observe 观察;associate 关联;administer 给药;recruit 招募;randomize 随机分组;analyze 分析 |
| 程度/频率副词 | significantly 显著地;markedly 明显地;substantially 大幅地;considerably 相当;modestly 适度地;slightly 轻微;approximately 大约;predominantly 主要地;consistently 一致地;frequently 频繁;rarely 罕见 |
| 逻辑连接词 | however 然而;therefore 因此;moreover 此外;furthermore 而且;in addition 另外;by contrast 相比之下;nevertheless 尽管如此;consequently 因此;although 尽管;whereas 而;despite 尽管;consistent with 与……一致 |
| 常见易混词 | affect(动词,影响)/ effect(名词,效应);compare to 比作 / compare with 比较;fewer 可数 / less 不可数;between 两者 / among 三者及以上;principal 主要的 / principle 原则;that 限定 / which 补充 |
| 拉丁缩写 | et al. 等人;e.g. 例如;i.e. 即;vs. 对比;etc. 等等;in vivo 体内 / in vitro 体外;per se 本身;a priori 先验 |
| 统计/计量 | odds ratio (OR) 比值比;hazard ratio (HR) 风险比;relative risk (RR) 相对危险度;confidence interval (CI) 置信区间;mean 均值;median 中位数;SD 标准差;IQR 四分位距;P value P 值 |
第二部分 零基础英文写作工具指南
2.1 工具使用总原则与数据保密
工具能显著降低英文写作门槛,但必须摆正位置:工具是语言助手,不是科学内容的作者。研究设计、数据真实性和结论由作者负责。请遵循以下总原则:
- 先逻辑、后语言:先用中文或简单英文理清研究逻辑、列出要点,再让工具处理语言,避免“让工具替你思考”。
- 分段处理、保留备份:以段落为单位处理,始终保留原始稿件和修改痕迹,便于核对与回退。
- 术语人工核对:专业名词、药名、剂量、数字和单位必须人工逐一核对,优先参照 MeSH、权威指南和期刊既往用法。
- 数据保密与脱敏:患者隐私和未发表数据不要随意上传公开工具;上传前去除姓名、住院号等可识别信息,有条件时使用本地或企业版工具。
- 工具会犯错:任何工具都可能误译、漏译或“一本正经地编造”,最终责任在作者,切勿全盘照抄。
2.2 翻译工具:正确用法与避坑
2.2.1 主流工具特点
- DeepL:译文语感自然、整句整段流畅,医学术语处理较可靠,适合正文翻译;但面对超长从句、复杂否定时可能漏译或自行“加戏”。
- Google 翻译:支持语种最全,提供网页与整篇文档翻译,适合“一带一路”多语种区域文献的快速理解。
- AI 翻译(ChatGPT、Claude、豆包等):可结合上下文、保持术语一致,并能指定“学术语体、英式/美式拼写”,灵活性最高。
2.2.2 正确用法与避坑点
- 01以段落为单位翻译,先建立统一的中英术语对照表,确保同一概念全篇一致。
- 02善用“回译”核验:把英文译文再翻回中文,检查是否与原意一致、有无信息增减。
- 03数字、单位、百分比、人名、日期单独核对,这些是机器最容易“悄悄出错”的地方。
- 04专业名词先查 MeSH 或权威术语,不要直接采用工具的字面翻译。
- 05避免整篇一翻了之、直接投稿;注意时态、单复数、否定词和口语化表达。
2.3 语法纠错工具:正确用法与避坑
- Grammarly:使用最广,可检查语法、拼写、标点、语气和部分学术风格,免费版即可满足基础需求;可能误判专业术语。
- Trinka:专为学术英语设计,熟悉医学术语,能检查学术语气与期刊规范,更贴合科研写作。
- LanguageTool:开源、可本地部署,隐私保护较好,适合处理敏感稿件。
- Word 内置“编辑器”:提供拼写、语法和可读性检查,无需额外上传,适合作为第一道关。
使用要点:先跑语法纠错,再人工审视逻辑;不要无脑“全部接受”,接受每条建议前读通整句;把专业术语加入自定义词典以减少误报;全文统一英式或美式拼写(如 behaviour/behavior、organisation/organization)。需要强调:语法工具不懂你的科学逻辑,它判“正确”的句子仍可能存在论证问题。
2.4 生成式 AI:提示词模板与学术诚信红线
生成式 AI(ChatGPT、Claude、Gemini、豆包等)适合用于头脑风暴、改写晦涩句子、检查逻辑、模拟审稿和翻译润色。关键是给出角色、任务、约束清晰的提示词。
可直接套用的提示词:
You are a medical editor. Rewrite the following paragraph in formal academic English suitable for an international medical journal. Keep the original meaning and all numerical data unchanged, and do not add any new claims.
Check the grammar and academic style of this Methods section. Explain each change briefly and keep all data unchanged.
Act as a strict peer reviewer. List the major weaknesses of this abstract and suggest concrete improvements.
Translate this Chinese paragraph into concise academic English, using the following terminology list: [terms].
学术诚信与署名红线(务必遵守):
- 禁止编造:不得让 AI 虚构数据、文献或引用。AI 会生成看似真实、实际并不存在的参考文献(“幻觉”),所有引用必须自行核实。
- 不能署名:AI 无法承担作者责任,不能列为作者;按 ICMJE/COPE 立场及目标期刊要求,在方法或致谢中如实披露 AI 的使用情况。
- 文责自负:查重、原创性和科学准确性仍由作者负责,AI 润色不构成免责理由。
2.5 改写降重工具的风险
QuillBot、Paraphraser 等同义改写工具通过替换词语“降重”,容易产生不地道或错误的搭配,且并不改变版权归属与重复实质。正确的降重方式是:读懂原文后用自己的语言重新组织,并正确引用出处;同时警惕自我抄袭、一稿多投和重复发表,而不是依赖机器替换蒙混查重。
2.6 推荐工具组合工作流
对零基础作者,推荐如下“流水线”,每一步都有人工核对环节:
- 01撰写中文/要点初稿,理清研究逻辑;
- 02用 DeepL 或 AI 翻译为英文初稿;
- 03对照术语表核对专业名词、药名与数字单位;
- 04用 Grammarly/Trinka 做语法纠错;
- 05用 AI 按学术语体润色(明确要求不改动数据、不新增结论);
- 06人工通读,并请导师或英语较好的同事/母语者审校;
- 07查重并按目标期刊格式排版后投稿。
| 工具 | 类型 | 核心用途 | 主要风险与避坑点 |
|---|---|---|---|
| DeepL | 翻译 | 正文整段翻译,语感自然 | 长从句/否定可能漏译,需回译核对 |
| Google 翻译 | 翻译 | 多语种、文档翻译 | 术语字面化,专业词需复核 |
| Grammarly | 语法纠错 | 语法、拼写、语气检查 | 误判术语,勿全部接受 |
| Trinka | 语法纠错 | 学术/医学英语与期刊规范 | 建议仍需结合逻辑判断 |
| LanguageTool | 语法纠错 | 可本地部署,隐私好 | 学术风格建议相对有限 |
| ChatGPT/Claude/豆包 | 生成式 AI | 翻译、润色、逻辑检查、模拟审稿 | 存在幻觉,禁造数据文献,需披露 |
| QuillBot | 改写降重 | 同义替换 | 易产生错误搭配,不改变版权实质 |
第三部分 国际投稿沟通礼仪
3.1 总体原则:正式、简洁、礼貌、留痕
- 正式:使用规范书面语,避免缩写、口语和感叹号(如用 do not 而非 don’t)。
- 简洁:一封邮件讲清一件事,开头即点明稿件题目和编号。
- 礼貌:即使有分歧或被拒稿,也保持专业、克制,不把情绪写进邮件。
- 留痕:优先通过期刊投稿系统沟通,重要事项同步邮箱并保存全部往来记录;同一事项保持在同一邮件线程内。
- 给足时间:尊重审稿周期,避免频繁催促;注意时区与截止时间。
3.2 投稿信(Cover Letter):结构与完整模板
投稿信是编辑对你的第一印象,通常包含:编辑称呼、稿件题目与类型、一句话核心发现与意义、原创性与独家声明、伦理与利益冲突、推荐/回避审稿人(可选)、规范落款。
Dear Dr. [Editor’s Surname] / Dear Editor-in-Chief,
On behalf of all co-authors, I am pleased to submit our manuscript entitled “[Full Title]” for consideration for publication as an Original Article in [Journal Name].
In this study, we found that [one-sentence key finding]. We believe these findings are important because [significance and relevance to the journal’s scope].
We confirm that this manuscript is original, has not been published previously, and is not under consideration by any other journal. All authors have read and approved the manuscript and agree to its submission. The study was approved by [ethics committee], and the authors declare no conflicts of interest.
[Optional] We suggest the following potential reviewers: [names, affiliations, emails]. We have no professional or financial relationship that would bias their assessment.
Thank you for your time and consideration. We look forward to your response.
Sincerely,
[Full Name], [Degree]
[Title, Affiliation] | Email: [address] | ORCID: [ID]
3.3 与编辑往来邮件:常用场景模板
3.3.1 礼貌询问稿件状态(催稿)
Dear Dr. [Surname],
I am writing to kindly inquire about the status of our manuscript entitled “[Title]” (Manuscript ID: [XXX]), submitted on [date].
We understand that peer review takes time and greatly appreciate your efforts. Please let us know if any further information is required from our side.
Sincerely, [Name]
3.3.2 申请延长修回期限
Dear Dr. [Surname],
Thank you for the opportunity to revise our manuscript (ID: [XXX]). Owing to [brief reason], we would be grateful if you could kindly extend the revision deadline to [date].
We will submit the revised manuscript together with a point-by-point response by that date. Thank you for your understanding.
Sincerely, [Name]
3.3.3 撤稿
Dear Dr. [Surname],
We regret to inform you that we must withdraw our manuscript “[Title]” (ID: [XXX]) from consideration, because [reason].
We sincerely apologize for any inconvenience this may cause and thank you for the time devoted to our submission.
Sincerely, [Name]
3.3.4 清样校对(Proof)
Dear Dr. [Surname] / Production Team,
Thank you for providing the proof. We have reviewed it carefully and have no further corrections. [Alternatively: We have listed the minor corrections in the attached file.]
Please let us know if anything else is needed. Sincerely, [Name]
此外,推荐审稿人应提供姓名、单位、邮箱和研究方向,并声明无利益关系;若对决定有异议需申诉(appeal),应基于事实、补充证据、礼貌提出,而不是情绪化反驳,且通常只有一次申诉机会。
3.4 审稿回复(Response to Reviewers):点对点规范
审稿回复是决定修回稿件能否被接收的关键,核心礼仪如下:
- 点对点回复:逐条引用审稿人意见,再给出对应回复,不遗漏、不回避。
- 感谢先行:先肯定意见的价值,即使不同意也保持尊重、专业。
- 标明位置:注明修改所在的页码、行号,并配合修订模式或颜色标注。
- 有理有据:不能修改之处要给出理由和文献支撑,而非简单拒绝。
回复信开头模板:
We thank the Editor and reviewers for their constructive comments, which have helped us substantially improve the manuscript. Our point-by-point responses are provided below.
Reviewer comments are shown in italics, and our responses in plain text. Revisions in the manuscript are marked in blue, and page/line numbers refer to the revised version.
同意并修改:
Comment 1: [reviewer’s exact comment]
Response: We thank the reviewer for this insightful comment. We agree and have accordingly [action]. The revised text on page [X], lines [Y–Z] now reads: “[new text].”
按建议补充分析:
Response: We have performed the additional analysis as suggested. The new results are presented in Supplementary Table [S1] and described on page [X], lines [Y–Z].
礼貌地保留不同意见:
Response: We appreciate this valuable suggestion; however, we respectfully disagree that [point], because [reason and evidence]. We have clarified this issue in the Discussion (page [X], lines [Y–Z]) and hope this adequately addresses the concern.
确实无法提供时:
Response: We agree that this information would be valuable; unfortunately, these data were not collected in our study and cannot be obtained retrospectively. We have acknowledged this as a limitation on page [X].
Once again, we thank the reviewers for their time and thoughtful comments, which have greatly strengthened our manuscript.
3.5 四类审稿决定的应对
| 决定类型 | 含义 | 正确应对 |
|---|---|---|
| Accept 接收 | 无需实质修改即可录用 | 及时处理版权、清样与归档,核对署名信息 |
| Minor revision 小修 | 小问题,修改后多可录用 | 逐条修改、按时返回,小修也认真对待 |
| Major revision 大修 | 需补充实验/分析或重写 | 视为机会,逐条充分回复,严守截止日期 |
| Reject 拒稿 | 当前不予录用 | 冷静读透意见,按意见改投或有充分依据才申诉,勿原样重投 |
3.6 称呼、落款、附件与语气细节
- 称呼:知道姓名用 “Dear Dr. [Surname]”;不知姓名用 “Dear Editors” 或 “Dear Editor-in-Chief”。
- 落款:全名、学位、职务、单位、邮箱与 ORCID,信息完整规范。
- 附件:命名清晰(如 ManuscriptID_Response.pdf),并在正文简要说明附件内容。
- 语气禁忌:不用口语缩写、感叹号,不催促、不威胁、不质疑审稿人人格。
- 时效:注意编辑所在时区与系统截止时间,尽量提前提交。
常用礼貌句式速查:
| 场景 | 英文表达 |
|---|---|
| 开头致谢 | Thank you for your time and helpful comments. |
| 提出请求 | We would be grateful if you could kindly ... |
| 表达歉意 | We apologize for any inconvenience this may have caused. |
| 确认理解 | We understand and appreciate the reviewer’s concern. |
| 结尾敬语 | We look forward to your response. / Sincerely, ... |
第四部分 “一带一路”区域医学期刊投稿特点
4.1 选刊先看什么:索引、费用与诚信核查
选刊比写作更需要“先看清楚”。建议依次核查以下维度,从源头避免投错刊或误入掠夺性期刊。
4.1.1 认识索引层级
- 国际主流:SCIE/SSCI(Web of Science)、PubMed/MEDLINE、Scopus、ESCI、PubMed Central、Embase,认可度和检索可见度最高。
- 开放获取目录:DOAJ 收录合规的开放获取期刊,是判断期刊正规性的重要参考。
- 区域索引:东南亚的 WPRIM、ASEAN Citation Index(ACI),俄语区的 RSCI,非洲的 African Index Medicus 等,反映区域内可见度。
4.1.2 识别掠夺性期刊(Predatory Journal)
常见“红旗”包括:主动发送垃圾邮件邀稿、承诺几天内快速录用或“保证发表”、缺乏清晰的同行评审流程、APC 费用不透明、刊名仿冒知名期刊、网站错误百出、查不到正规索引和真实编委。可借助 DOAJ 目录、Think Check Submit 原则、Scimago Journal Rank(SJR) 并回到期刊官网核实 ISSN、DOI、出版社与编委信息。
4.2 中亚地区:多语种并存与 Scopus 转型
中亚(哈萨克斯坦、乌兹别克斯坦、塔吉克斯坦、吉尔吉斯斯坦、土库曼斯坦)医学期刊普遍存在俄语、本地语言、英语多语种并存的局面:老牌期刊多以俄语为主,而年轻的、定位国际化的期刊越来越多地采用英文。
- 进入 Scopus 的门槛是英语与规范评审:例如塔吉克斯坦的 Avicenna Bulletin 已于 2023 年被 Scopus 收录,同时也在 Embase、DOAJ、RSCI 等平台;这说明区域刊正通过提升英文质量和同行评审走向国际。
- 先确认当前语言与索引状态:部分期刊同时收录俄文与英文稿件,不同语种的检索可见度和被引机会差异明显。
- 关注本地认定名单:当地学位、职称评定往往认可特定索引(如 HAC/VAK 名单),投稿前结合自身用途确认。
- 勿降低语言标准:即使是区域刊,英文稿仍需地道、规范;本地人群、地方病和传统医学相关研究在这类期刊更受欢迎。
4.3 东南亚地区:与国际规范接轨、区域索引成熟
东南亚(泰国、印度尼西亚、马来西亚、菲律宾、越南、新加坡等)医学期刊与国际规范接轨程度较高,头部期刊(如 The Lancet Regional Health – Southeast Asia)明确遵循 ICMJE 推荐规范与 COPE 出版伦理。
- 区域索引成熟:除 Scopus/PMC 外,还有 WHO 西太平洋区医学索引(WPRIM)和东盟引文索引(ACI)。例如菲律宾 Acta Medica Philippina 同时被 PMC、Scopus、WPRIM、ACI 收录。
- 费用差异大:部分期刊不收取文章处理费(APC),投稿前确认,避免预算意外。
- 注意英语拼写:部分期刊指定使用美式英语拼写;作者指南中对表格、图表格式有具体要求,应严格照做。
- 语言帮助有限:编辑部可能提供有限的语言协助,但提前自行润色能明显加快处理速度。
- 议题偏好:热带病、传染病、公共卫生、基层医疗和区域人群数据。
4.4 中东地区:英文出版、伦理与注册把关严格
中东(沙特、阿联酋、卡塔尔、阿曼、黎巴嫩、埃及、约旦等)面向国际的医学期刊多仅以英文出版,双盲审稿常见,并强调由单一通信作者全程负责沟通、伦理审批、临床试验注册和利益冲突表单。
- 伦理与注册把关严:伦理委员会批件、知情同意、临床试验注册(ICMJE 要求)需齐全,缺项容易直接退稿。
- 平台规范:不少期刊由大学或 Elsevier、Springer 等平台托管,流程标准化;ICMJE 还提供阿拉伯语译本帮助本地理解,但投稿仍须用英文。
- 署名权责清晰:作者贡献、单位和通信作者责任要求明确,对一稿多投、重复发表审查严格。
- 议题偏好:糖尿病、肥胖、心血管、遗传病及本地流行病学、沙漠相关疾病。
4.5 非洲地区:本地疾病议题友好、声明要求明确
非洲(南非、尼日利亚、肯尼亚、埃塞俄比亚、埃及及法语区等)医学期刊多由专业学会和大学出版,常依赖志愿者编辑、资源有限,审稿多为双盲,周期常见约 4–6 周,但各刊差异较大。
- 重视各类声明:利益冲突、资助来源、数据可用性、伦理审批缺一不可;即使没有利益冲突,也要明确写 “none declared”。
- 议题偏好鲜明:疟疾、结核、HIV、母婴健康、传染病、卫生体系及资源有限环境(LMIC)下的临床研究。这类议题在西方期刊常被认为“过于基础”,区域期刊反而欢迎。
- 语言分区:英语区占多数,同时存在法语区(如刚果民主共和国的 Annales africaines de médecine),投稿前确认语言要求。
- 出版与索引差异大:部分入 PubMed/Scopus,多数仅在区域索引(如 African Index Medicus);出版周期可能不稳定,开放获取比例高,留意 APC 及面向低收入地区的减免政策。
4.6 区域对照表与通用投稿检查清单
| 区域 | 主要语言 | 常见索引/规范 | 议题偏好 | 特别注意 |
|---|---|---|---|---|
| 中亚 | 俄语/本地语/英语 | Scopus、RSCI、DOAJ;HAC/VAK 名单 | 地方病、本地人群、传统医学 | 确认当前语言与索引,勿降低英文标准 |
| 东南亚 | 英语(部分美式) | Scopus、PMC、WPRIM、ACI;ICMJE/COPE | 热带病、传染病、公共卫生 | 图表格式严格,部分无 APC |
| 中东 | 英语 | Scopus、PMC;ICMJE/COPE,双盲 | 糖尿病、肥胖、心血管、遗传病 | 伦理批件与试验注册必须齐全 |
| 非洲 | 英语/法语 | PubMed、Scopus、African Index Medicus | 疟疾、结核、HIV、卫生体系 | 声明齐全,留意周期与 APC 减免 |
结语:投稿前最终检查清单与心态建议
正式点击“提交”前,建议对照以下清单逐项确认(可打印后勾选):
□ 选题与期刊范围(Aims & Scope)匹配,文章类型符合要求
□ 字数、页数、参考文献数量与格式符合作者指南
□ 结构式摘要完整,关键词数量与术语规范
□ 图表清晰、编号正确,表题/图题位置与格式无误
□ 伦理批件、知情同意、临床试验注册齐全
□ 利益冲突、基金、数据可用性、作者贡献声明完整
□ 投稿信(Cover Letter)信息准确,已附推荐/回避审稿人(如需要)
□ 已完成查重,文件命名规范,已注册 ORCID
□ 全文通读,数字、单位、药名、时态与拼写核对无误
最后给零基础作者三句心态建议:第一,学术写作是一门可以学习的技能,没有人天生会写,规范句式和模板是最好的起点;第二,先完成、再完美,先把骨架和数据填完整,语言可以借助工具和同事逐步打磨;第三,善用工具但守住底线——让工具帮你解决语言,却永远让自己守住科学真实、数据准确和学术诚信。从一篇病例报告、一次规范投稿开始,你就已经走在大多数同行前面。
